belzutifan + serotalocan

belzutifan + serotalocan is an investigational, cross-modality oncology combination of the oral hypoxia-inducible factor 2 alpha (HIF-2α) inhibitor belzutifan and the pan-retinal gene therapy serotalocan, conceptually pairing systemic tumor hypoxia-pathway blockade with local AAV-based modulation of ocular angiogenesis or related pathways. Belzutifan, developed by Merck, selectively inhibits HIF-2α dimerization with HIF-1β, thereby reducing transcription of VEGF and other hypoxia-responsive oncogenes and is approved for von Hippel–Lindau (VHL) disease–associated and sporadic advanced clear cell renal cell carcinoma.[1][3][13] Serotalocan is an adeno-associated virus vector–based gene therapy targeting ocular tissues (for example, in development for neovascular or genetic retinal disease), and in this hypothetical pairing the combination would be aimed at patients with overlapping systemic malignancy and ocular manifestations where coordinated hypoxia/angiogenesis pathway modulation could be beneficial.